These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12463140)

  • 1. [Metastatic kidney cancer: new therapeutic approaches].
    Negrier S; Mejean A; Oudard S; Escudier B
    Prog Urol; 2002 Sep; 12(4):703-8. PubMed ID: 12463140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies].
    Ferrière JM; Wallerand H; Bernhard JC; Cornu JN; Rouprêt M; Ravaud A
    Prog Urol; 2008 Jul; 18 Suppl 4():S88-91. PubMed ID: 18706377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up.
    Nakagawa T; Kami M; Hori A; Kim SW; Murashige N; Hamaki T; Kishi Y; Fujimoto H; Matsuoka N; Okajima E; Komiyama M; Tobisu K; Wakayama T; Uike N; Tajima K; Makimoto A; Mori S; Tanosaki R; Takaue Y; Kakizoe T
    Exp Hematol; 2004 Jul; 32(7):599-606. PubMed ID: 15246155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic stem cell transplantation for patients with metastatic renal cell carcinoma.
    Roigas J; Johannsen M; Ringsdorf M; Massenkeil G
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1449-58. PubMed ID: 17069529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conclusion and future directions.
    Samlowski WE; Vogelzang NJ
    Cancer J; 2008; 14(5):330-2. PubMed ID: 18836339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine and vaccine therapy of kidney cancer.
    Doehn C; Kausch I; Melz S; Behm A; Jocham D
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1097-111. PubMed ID: 15606336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
    J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatments for metastatic kidney cancer.
    Mancuso A; Sternberg CN
    Can J Urol; 2005 Feb; 12 Suppl 1():66-70; discussion 105. PubMed ID: 15780170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephron-sparing surgery for renal cell carcinoma in the solitary kidney.
    Berdjis N; Hakenberg OW; Novotny V; Manseck A; Oehlschläger S; Wirth MP
    Scand J Urol Nephrol; 2007; 41(1):10-3. PubMed ID: 17366096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debulking nephrectomy in metastatic renal cancer.
    Flanigan RC
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6335S-41S. PubMed ID: 15448027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel antiangiogenic therapies for renal cell cancer.
    Gordon MS
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6377S-81S. PubMed ID: 15448034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting cancer-control outcomes in patients with renal cell carcinoma.
    Karakiewicz PI; Hutterer GC
    Curr Opin Urol; 2007 Sep; 17(5):295-302. PubMed ID: 17762620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer.
    Kuczyk M; Wegener G; Jonas U
    Eur Urol; 2005 Aug; 48(2):252-7. PubMed ID: 15936136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
    Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
    Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic approaches in metastatic renal cell carcinoma.
    Staehler M; Rohrmann K; Bachmann A; Zaak D; Stief CG; Siebels M
    BJU Int; 2005 Jun; 95(8):1153-61. PubMed ID: 15877725
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
    Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiangiogenic treatment and kidney cancer: ongoing trials and future perspectives].
    Oudard S; Cornu JN; Rouprêt M; Patard JJ
    Prog Urol; 2008 Jul; 18 Suppl 4():S77-80. PubMed ID: 18706375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.